Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide

Dilip Unnikrishnan; Janice P. Dutcher; Nikita Varshneya; Richard Lucariello; Marietta Api; Susan Garl; Peter H. Wiernik; Salvatore Chiaramida

doi:10.1182/blood.V97.5.1514

Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide

Dilip Unnikrishnan, Janice P. Dutcher, Nikita Varshneya, Richard Lucariello, Marietta Api, Susan Garl, Peter H. Wiernik, Salvatore Chiaramida

Research output: Contribution to journal › Article › peer-review

170 Scopus citations

Abstract

Arsenic trioxide is used in clinical trials in the treatment of relapsed and resistant cases of acute promyelocytic leukemia. Adverse effects from arsenic in these studies have been multisystemic. Arsenic is known to cause corrected QT-interval prolongation and T-wave changes, but the potential for serious ventricular arrhythmias is less well understood. Torsades de pointes, a form of ventricular tachycardia, has been reported with arsenic poisoning but not at therapeutic doses used in protocols for hematologic malignancies. We describe 3 patients in whom this arrhythmia developed while they were treated with arsenic trioxide. Early recognition of the arrhythmia or correction of contributory factors is important because arsenic induced ventricular arrhythmias ere known to be resistant to most chemical methods and electrical cardioversion.

Original language	English (US)
Pages (from-to)	1514-1516
Number of pages	3
Journal	Blood
Volume	97
Issue number	5
DOIs	https://doi.org/10.1182/blood.V97.5.1514
State	Published - Mar 1 2001
Externally published	Yes

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood.V97.5.1514

Cite this

@article{71d7904a51554426b8fec56ece7dbd06,

title = "Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide",

abstract = "Arsenic trioxide is used in clinical trials in the treatment of relapsed and resistant cases of acute promyelocytic leukemia. Adverse effects from arsenic in these studies have been multisystemic. Arsenic is known to cause corrected QT-interval prolongation and T-wave changes, but the potential for serious ventricular arrhythmias is less well understood. Torsades de pointes, a form of ventricular tachycardia, has been reported with arsenic poisoning but not at therapeutic doses used in protocols for hematologic malignancies. We describe 3 patients in whom this arrhythmia developed while they were treated with arsenic trioxide. Early recognition of the arrhythmia or correction of contributory factors is important because arsenic induced ventricular arrhythmias ere known to be resistant to most chemical methods and electrical cardioversion.",

author = "Dilip Unnikrishnan and Dutcher, {Janice P.} and Nikita Varshneya and Richard Lucariello and Marietta Api and Susan Garl and Wiernik, {Peter H.} and Salvatore Chiaramida",

year = "2001",

month = mar,

day = "1",

doi = "10.1182/blood.V97.5.1514",

language = "English (US)",

volume = "97",

pages = "1514--1516",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "5",

}

TY - JOUR

T1 - Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide

AU - Unnikrishnan, Dilip

AU - Dutcher, Janice P.

AU - Varshneya, Nikita

AU - Lucariello, Richard

AU - Api, Marietta

AU - Garl, Susan

AU - Wiernik, Peter H.

AU - Chiaramida, Salvatore

PY - 2001/3/1

Y1 - 2001/3/1

N2 - Arsenic trioxide is used in clinical trials in the treatment of relapsed and resistant cases of acute promyelocytic leukemia. Adverse effects from arsenic in these studies have been multisystemic. Arsenic is known to cause corrected QT-interval prolongation and T-wave changes, but the potential for serious ventricular arrhythmias is less well understood. Torsades de pointes, a form of ventricular tachycardia, has been reported with arsenic poisoning but not at therapeutic doses used in protocols for hematologic malignancies. We describe 3 patients in whom this arrhythmia developed while they were treated with arsenic trioxide. Early recognition of the arrhythmia or correction of contributory factors is important because arsenic induced ventricular arrhythmias ere known to be resistant to most chemical methods and electrical cardioversion.

AB - Arsenic trioxide is used in clinical trials in the treatment of relapsed and resistant cases of acute promyelocytic leukemia. Adverse effects from arsenic in these studies have been multisystemic. Arsenic is known to cause corrected QT-interval prolongation and T-wave changes, but the potential for serious ventricular arrhythmias is less well understood. Torsades de pointes, a form of ventricular tachycardia, has been reported with arsenic poisoning but not at therapeutic doses used in protocols for hematologic malignancies. We describe 3 patients in whom this arrhythmia developed while they were treated with arsenic trioxide. Early recognition of the arrhythmia or correction of contributory factors is important because arsenic induced ventricular arrhythmias ere known to be resistant to most chemical methods and electrical cardioversion.

UR - http://www.scopus.com/inward/record.url?scp=0035283137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035283137&partnerID=8YFLogxK

U2 - 10.1182/blood.V97.5.1514

DO - 10.1182/blood.V97.5.1514

M3 - Article

C2 - 11222403

AN - SCOPUS:0035283137

SN - 0006-4971

VL - 97

SP - 1514

EP - 1516

JO - Blood

JF - Blood

IS - 5

ER -

Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this